Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

October 15, 2013; 81 (16) Article

Preclinical AD predicts decline in memory and executive functions in subjective complaints

Argonde C. van Harten, Lieke L. Smits, Charlotte E. Teunissen, Pieter J. Visser, Teddy Koene, Marinus A. Blankenstein, Philip Scheltens, Wiesje M. van der Flier
First published September 18, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182a8418b
Argonde C. van Harten
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lieke L. Smits
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte E. Teunissen
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pieter J. Visser
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teddy Koene
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marinus A. Blankenstein
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Scheltens
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wiesje M. van der Flier
From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.), School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Preclinical AD predicts decline in memory and executive functions in subjective complaints
Argonde C. van Harten, Lieke L. Smits, Charlotte E. Teunissen, Pieter J. Visser, Teddy Koene, Marinus A. Blankenstein, Philip Scheltens, Wiesje M. van der Flier
Neurology Oct 2013, 81 (16) 1409-1416; DOI: 10.1212/WNL.0b013e3182a8418b

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
454

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: We assessed whether preclinical Alzheimer disease (AD) based on CSF biomarkers at baseline predicts decline in cognitive functioning as measured by repeated neuropsychological tests for 4 cognitive domains in patients with subjective complaints.

Methods: We included 132 patients with subjective complaints from our memory clinic–based Amsterdam Dementia Cohort, who underwent lumbar puncture and had repeated (range 2–7) neuropsychological evaluations. Follow-up was 2 ± 1 years. CSF biomarkers amyloid-β (Aβ42), total tau (Tau), and hyperphosphorylated tau-181 were used to define National Institute on Aging–Alzheimer's Association (NIA-AA) preclinical AD stages. Predictive value of preclinical AD stages as defined by CSF biomarkers, individual biomarkers, and Aβ42/tau ratio was assessed using linear mixed models. Outcome measures were compound z scores for memory, attention, executive functioning, language, and global cognition. Analyses were adjusted for age, sex, and education.

Results: Patients were 61 ± 8 years old; 56 (42%) were women. Average baseline Mini-Mental State Examination score was 28.3 ± 1.5. Patients who fulfilled criteria for preclinical AD (stage 1: n = 11 + stage 2: n = 10) showed decline over time in memory (β ± SE −0.41 ± 0.14, p < 0.01), executive functions (−0.21 ± 0.08, p < 0.01), and global cognition (−0.29 ± 0.10, p < 0.01). There were no differences in cognitive decline between NIA-AA preclinical AD stages 1 and 2. In patients with normal CSF biomarkers, we observed memory improvement (0.19 ± 0.07, p < 0.01) and stable performance in all other domains.

Conclusions: CSF evidence of preclinical AD in patients with subjective complaints predicted cognitive decline over time, encompassing more than memory alone. Executive functioning and global cognitive functioning also deteriorated. On the other hand, 2-year prognosis for patients without evidence of AD pathophysiology was good.

GLOSSARY

Aβ42=
amyloid-β;
AD=
Alzheimer disease;
MCI=
mild cognitive impairment;
NIA-AA=
National Institute on Aging–Alzheimer's Association;
pTau=
hyperphosphorylated tau-181;
RAVLT=
Rey Auditory Verbal Learning Task;
SNAP=
suspected non-Alzheimer pathway;
Tau=
total tau;
TMT=
Trail Making Test;
VAT=
Visual Association Test

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at www.neurology.org

  • Received April 4, 2013.
  • Accepted in final form July 11, 2013.
  • © 2013 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Topics Discussed

  • Alzheimer's disease
  • Natural history studies (prognosis)
  • Cognitive neuropsychology in dementia

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
    Daniel Alcolea, Pablo Martínez-Lage, Pascual Sánchez-Juan et al.
    Neurology, July 15, 2015
  • Article
    Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
    Catherine M. Roe, Anne M. Fagan, Elizabeth A. Grant et al.
    Neurology, April 10, 2013
  • Articles
    Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
    D.S. Knopman, C.R. Jack, Jr., H.J. Wiste et al.
    Neurology, May 02, 2012
  • Articles
    Longitudinal changes of CSF biomarkers in memory clinic patients
    F. H. Bouwman, W. M. van der Flier, N.S.M. Schoonenboom et al.
    Neurology, September 04, 2007
Neurology: 101 (14)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise